Home Cardiocycle's SteerFar QuYou®—World’s Smallest (1.7F) and Most Comprehensive Controllable Microcatheter—Receives NMPA Approval

Cardiocycle's SteerFar QuYou®—World’s Smallest (1.7F) and Most Comprehensive Controllable Microcatheter—Receives NMPA Approval

Jul 24, 2025 22:40 CST Updated 22:40
CardioCycle

Innovative Medical Device Developer

Image


Recently, CardioCycle Technology (Suzhou) Co., Ltd. ("CardioCycle"), an outstanding company invested in by Daoyuan,The SteerFar Flex® Controllable Microcatheter, the world's smallest (1.7F) and most comprehensive specification, has officially received marketing approval from the National Medical Products Administration (NMPA).(Registration Certificate No.: China Medical Device Registration 20253031436).


Image


SteerFar® Defines Dual Limits of the Industry


1. The world's most comprehensive specification matrix

  • Outer Diameter Range: 1.7F-2.7FOffering 5 outer diameter specifications (1.7F/1.9F/2.1F/2.4F/2.7F), compatible with more devices, providing a complete access solution.

  • Dual Length Design: 125cm (Radial Artery Optimized), 150cm (Femoral Artery/Long Pathway Adapted),Achieve precise access matching.


Image


2. Smallest global outer diameter (1.7F)

  • Breakthrough in passability bottleneck: 1.7F outer diameter(Approx. 0.57mm) is currently the globally available steerable microcatheterMinimum value.


Image


Application of Controllable Bend Microcatheters in the Cardiovascular Field


1. Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention

In complex CTO lesions with ambiguous proximal fibrous cap, tortuous collateral vessels, or requiring reverse CART technique, steerable microcatheters can be applied:

  • Entering branch vessels

  • Re-enter the True Lumen

  • Delivery of guidewire in acute branch

Advantages: Reducing the need for guidewire pre-shaping, enhancing the controllability of microchannel navigation.


2. Structural Heart Interventions

Especially in the application of atrial septal puncture and left atrium navigation:

  • Mitral Valve Intervention

  • Left Atrial Appendage Occlusion

  • Paravalvular Leak Closure

  • Delivery of Steerable Sheath

Advantage: Precise alignment with the fossa ovalis or the opening of the left atrial appendage, reducing fluoroscopy time.


3. Peripheral Vascular Intervention (PVI)

  • Complex occlusive lesions through the iliac artery, superficial femoral artery, or tibial artery

  • Embolization procedure involving branch vessels (e.g., uterine fibroids, endoleaks)

Advantage: The deflectable tip helps bypass calcified plaques or tortuous branches.


Image


4. Cardiac Electrophysiology Monitoring and Ablation (EP)

  • For pulmonary vein isolation, atrial mapping, and ablation therapy

  • Some electrophysiological catheters integrate steering control with mapping sensor functions.

Advantages: Achieve precise positioning and ensure stable contact with the endocardial surface.


CardioCycle-SteerFar®


SteerFar®The aboveCity,Marks a significant achievement for China in the high-end microcatheter field"World's Smallest" and "FullThe "most comprehensive in the world" dual breakthrough.

CardioCycle Technology will continue to drive the globalization of precision interventional treatment with innovative strength.




About CardioCycle

CardioCycle was founded in 2021, focusing on providing one-stop solutions for interventional therapy. It covers cardiac intervention and pan-vascular intervention. Production and R&D centers have been established in Biobay, Suzhou, and GMIT, Galway, Ireland. The company is committed to becoming an interventional medical solution provider that deeply cultivates research and development and manufacturing, serving patients and contributing globally.



About Daoyuan Capital

Daoyuan Capital is a leading private equity investment institution focused on the healthcare sector, dedicated to helping outstanding healthcare companies grow rapidly by leveraging capital and industry resources, providing better medical products and services to society, and promoting human health.


Currently, Daoyuan Capital manages 21 RMB funds and 4 USD funds, with a total of 92 outstanding projects invested, including 16 IPO projects (one of which has obtained the CSRC registration approval), such as Aier Eye Hospital (301239), Jinxin Fertility (HK.1951), Sinomed (688108), Innovax (688253), TiRobot (688277), Viva Biotech (HK.1873), Anbiping (688393), and Anges (688581). In the next three years, more than 10 invested companies are expected to enter the IPO process.


Image